Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WestVac Biopharma Approved to Launch COVID-19 Vaccine for XBB Variants

publication date: Jun 9, 2023

Chengdu WestVac Biopharma announced that its Trivalent COVID-19 vaccine targeting XBB variants was approved for emergency use in China. The vaccine, named Coviccine®, is the first vaccine approved globally to target XBB variants. It was developed by WestVac Biopharma/West China Medical Center, Sichuan University. WestVac used an insect cell expression platform to construct the vector for Coviccine®, an XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 Cell). The company worked with its subsidiary WestVac Biopharma (Guangzhou) to develop the vaccine. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital